Background: Cutaneous melanoma is the most deadly form of skin cancer with more than 8000 deaths per year in the United States. The health burden and economic costs associated with melanoma mortality by race/ethnicity have not been appropriately addressed.
Cutaneous melanoma (hereafter called melanoma) is the third most common form of skin cancer after basal and squamous cell carcinomas. It is a deadly form of skin cancer with more than 8000 deaths per year. 1 The average lifetime risk of developing melanoma in the United States has increased from 1 in 1500 in 1935 to 1 in 30 in 2009. 2, 3 As a result, the health burden measured by mortality associated with melanoma has increased over time and is reported to disproportionately affect non-Hispanic whites and other racial/ethnic groups with fair-skinned complexion. 4, 5 Quantifying health status in human populations is often measured by mortality; however, mortality does not fully address the issue of premature deaths, particularly among younger populations. 6, 7 An alternative measure to use is years of potential life lost (YPLL), which provides a more accurate measure of mortality for the young and the elderly population. 7, 8 The burden of melanoma disease measured by using YPLL by race/ethnicity has not been satisfactorily addressed.
The economic costs associated with melanoma have been estimated to be substantial. Past studies have reported the costs of melanoma using various economic methods. [9] [10] [11] For instance, Bickers et al 9 (2006) and Bradley et al 10 (2008) used the human capital approach (HCA) to estimate the cost of lost productivity caused by melanoma to range from $2.9 billion in 2004 dollars to $3.3 billion in 2010 dollars. The HCA values labor and household productivity that an individual contributes to society. 12 Alternatively, Yabroff et al 11 (2008) used the willingness-to-pay method to estimate the value of life lost to society as a result of melanoma to be $15.1 billion in 2000 dollars with a projected increase to $21.6 billion in 2020. The willingness-to-pay method measures the amount of money or resources an individual would pay to reduce the probability of illness or dying from melanoma. 13 This method is more comprehensive as it includes costs of lost productivity and intangible costs such as pain and suffering caused by melanoma. These economic studies have provided strong evidence of the substantial costs attributed to melanoma at the societal level. However, information on economic costs associated with melanoma among racial/ethnic groups is not currently available in the literature.
The purpose of this study is 2-fold: first, we quantified the health burden associated with melanoma mortality measured by YPLL. Second, we estimated the economic costs associated with melanoma mortality measured by the value of lifetime productivity losses. We compared the findings with estimates from 4 major cancers (ie, female breast [breast], prostate, colorectal, and lung/bronchus [lung] ) and all malignant cancers. All the estimates were stratified by race/ethnicity.
METHODS
We used 3 broad measures of disease burden to quantify the magnitude of melanoma and compared its impact relative to the 4 major cancers listed above and against all malignant cancers. These burden measures included mortality, YPLL, and the value of productivity losses from mortality. Mortality associated with melanoma, the 4 major cancers, and all malignant cancers were used in conjunction with data from the US life tables, and from the literature to estimate YPLL and the value of productivity loss caused by mortality. We constructed a model of disease burden to estimate foregone lifetime productivity lost in terms of incidence-based costs as opposed to prevalence-based costs.
14-16 Productivity losses were measured using the HCA. [17] [18] [19] This approach values labor productivity acquired through an investment in education, on-the-job training, and work experience, 20 and the value of nonwage labor productivity performed in the household.
Data sources and extraction
We used the Surveillance, Epidemiology, and End Results (SEER)*Stat software (Version 6. The results presented in this article should be viewed as one of the best available estimates to quantify the burden of melanoma mortality by race/ ethnicity compared with 4 major cancers and all malignant cancers.
cancer mortality and associated population data that cover 100% of US deaths. 21 The mortality data from SEER*Stat for melanoma; breast, prostate, colorectal, and lung cancer; and for all malignant cancers from 2000 to 2006 were obtained from the Centers for Disease Control and Prevention National Vital Statistics Surveillance System. 22 Mortality from melanoma and the 4 major cancers were coded as the underlying cause of death at primary cancer site using the International Statistical Classification of Diseases, 10th Revision with C43 for melanoma; C50 for breast, C61 for prostate, C18 to C21 for colorectal, and C33 to C34 for lung cancers; and C00 to C97 for all malignant cancers. 23 The population denominator data from SEER*Stat were used for calculating crude rates and age-adjusted rates were obtained from the 2000 US Census. 24 All rates are expressed per 100,000 population. We extracted data on individuals aged 15 years or older, by 5-year age groups and sex. We excluded individuals aged 0 to 14 years because no deaths from melanoma were reported in this age group. We constructed 4 mutually exclusive racial/ethnic categories: non-Hispanic white, nonHispanic black, non-Hispanic other (ie, Asian/ Pacific Islanders and American Indian/Alaska Natives), and Hispanic.
Estimation of YPLL, average YPLL, YPLL rates, and age-adjusted rates
We used the life expectancy method to calculate YPLL 7, 8, 16 rather than using an arbitrary age cutoff of 70 or 75 years that has been used in previous studies. [25] [26] [27] This method is defined as the expected YPLL because of a particular disease, such as melanoma, during an individual's lifetime. 8 We believed that this approach is appropriate in particular to cancer where the majority of deaths are highly skewed toward the elderly population. Based on this method, we calculated YPLL in each 5-year age group by the corresponding remaining life expectancy obtained from the 2000 to 2006 US life tables. [28] [29] [30] [31] [32] [33] [34] [35] The estimated number of YPLL in each 5-year age group was summed to obtain the total YPLL for melanoma, 4 major cancers, and all malignant cancers in individuals aged 15 years or older. The estimation was stratified by race/ethnicity and sex. Because current life tables do not report life expectancy for Asian/Pacific Islanders and American Indian/Alaska Natives, we used the life tables data on all races as a proxy for non-Hispanic other. [28] [29] [30] [31] [32] [33] [34] [35] To compare YPLL across racial/ethnic groups, we estimated crude and age-adjusted rates (YPLL/100,000 population). Age-adjusted rates were calculated by the direct method, using the 2000 US standard population by 5-year groups. 36 Further, we examined mortality from melanoma and other major cancers in non-Hispanic whites compared with each racial/ ethnic group by calculating rates and rate ratios. We used the YPLL rates in non-Hispanic whites as the referent. In addition to the estimation of YPLL, we also calculated average YPLL, crude rates, and rate ratios by race/ethnicity. We also calculated absolute change in mortality and YPLL for 2000 and 2006, percent change, and percent contribution of each of the 4 major cancer sites compared with melanoma.
Estimation of mortality costs
Productivity costs caused by premature mortality from melanoma, 4 other major cancers, and all malignant cancers were estimated using the number of deaths in 2006 multiplied by the present value of future lifetime earnings (PVFLE) stratified by age, sex, and race/ethnicity. The data on the PVFLE were obtained from a published study. 37 The PVFLE estimate took into account factors such as life expectancy, labor force participation rate, future growth rate in productivity, and imputed value of housekeeping services (eg, cooking, cleaning, childcare). We applied a 3% discount rate in estimating the PVFLE and examined how our results changed when we applied a 0% and a 5% discount rate. The discount rate was used to convert future earnings for these people who died to present value. 13 In addition to estimating the total PVFLE lost caused by melanoma mortality, we also estimated the total PVFLE from 4 major cancers and all malignant cancers. We also estimated the cost of premature death on an individual level. All costs presented in this study were standardized to 2006 US dollars.
RESULTS

Years of potential life lost
In 2000 and 2006, a total of 7419 and 8437 Americans died from melanoma, respectively, which represented an increase of 1018 (13.7%) deaths. These deaths accounted for an estimated 152,912 to 166,261 YPLL, representing an increase of 13,349 (8.7%) in premature mortality from 2000 to 2006 compared with 2.8% premature mortality for all malignant cancers (Table I) . On average, an Total excludes data from all malignant cancers. # Grand total is the combination of the following major cancers: melanoma, breast, colorectal, prostate, and lung and bronchus. For the four major cancers (ie, breast, colorectal, prostate, and lung and bronchus) the estimated YPLL per death was 16.2. individual in the United States could lose 20.4 years of potential life during his or her lifetime because of melanoma mortality, which is greater than 16.2 years for the 4 major cancers (ie, breast, prostate, colorectal, and lung), and 16.6 years for all malignant cancers.
For men, we estimated an increase of 883 deaths caused by melanoma and an estimated increase of 12,432 YPLL. This estimate represents an 18.9% increase in melanoma contribution to mortality among the 4 major cancers. These 4 major cancers contributed to a 25% to 58% decrease in cancer mortality (Table I) 
In general, men had a 6.5 times (883/135) higher mortality from melanoma than women. However, on an individual basis, the impact of premature mortality measured by YPLL per death was higher in women (21.4) than in men (19.0). This implies that although men may have higher mortality burden associated with melanoma, the disease affects women at a younger age. This point is clearly illustrated in Fig 1, which demonstrates that the proportion of YPLL as a result of melanoma relative to YPLL from all malignant cancers varied by age and sex. Overall, men had the largest relative contribution to YPLL starting from age 25 years through the remainder of their lives, with the greatest contribution at age 30 to 34 years. On the other hand, women have relative contributions to YPLL starting at age 20 years through the remainder of their lives, with the greatest contribution at age 25 to 29 years.
We estimated 1.1 million (95.5%) YPLL as a result of melanoma in non-Hispanic whites, 25,337 (2.3%) in Hispanics, and 14,861 (1.3%) in non-Hispanic blacks (Table II) . For non-Hispanic whites, the estimated YPLL rate was 87.7 per 100,000. Using non-Hispanic whites as the reference group the estimated YPLL rate ratio ranged from 0.1 to 0.2 for non-Hispanic blacks and Hispanics, respectively.
Melanoma accounted for 1.8% of the estimated 63.6 million YPLL among all malignant cancers. Among the 4 major cancers and melanoma, we estimated a total of 32.8 million YPLL from 2000 to 2006; of which, melanoma accounted for 3.4%. Prostate accounted for 6.1%, colorectal and breast cancers each accounted for 17.6%, and lung accounted for 55.2% (Table II) . In the past 7 years, these 4 major cancers and melanoma accounted for an average of 52.6% of mortality and 51.6% of YPLL that have occurred among all malignant cancers (data not shown). The relative contributions of each of these 4 cancer sites to mortality and YPLL are presented in Appendix 2.
Mortality-related productivity costs
In 2006, the estimated lifetime cost associated with melanoma mortality discounted at 3% rate was $3.5 billion (discount rate range from 5%-0%: $2.9-$5.1 billion) (Table III) . At an individual level, we estimated this cost to be $413,370 (discount rate range from 5%-0%: $338,469-$602,265) per death. Deaths among men accounted for $2.4 billion (discount rate range from 5%-0%: $2.0-$3.5 billion) of lost productivity (or 67.1% of the total), with an average cost per death of $441,903 (discount rate range from 5%-0%: $365,268-$630,438). Deaths among women accounted for $1.2 billion (discount rate range from 5%-0%: $0.9-$1.8 billion) of lost productivity (or 32.9% of the total), with an average cost per death of $401,046 (discount rate range from 5%-0%: $324,925-$598,214).
In the order of lowest to highest, the estimated racial/ethnic-specific lifetime mortality cost associated with melanoma was $28.6 million (discount rate range from 5%-0%: $23.1-$43.3 million) with an average cost per death of $461,795 (discount rate range from 5%-0%: $372,372-$697,735) for nonHispanic other; $50.9 million (discount rate range from 5%-0%: $41.5-$75.1 million) with average cost per death of $413,913 (discount rate range from 5%-0%: $337,063-$610,804) for non-Hispanic blacks; $110.8 million (discount rate range from 5%-0%: $88.4-$170.5 million) with average cost per death of $545,795 (discount rate range from 5%-0%: $435,604-$840,317) for Hispanics; and $3.3 billion (discount rate range from 5%-0%: $2.7-$4.8 billion) with average cost per death of $409,814 (discount rate range from 5%-0%: $335,910-$595,654) for non-Hispanic whites.
DISCUSSION
In this study, we quantified the burden of melanoma mortality measured by YPLL and the associated economic costs by race/ethnicity from 2000 to 2006. The results were summarized in two broad measures of cancer disease burden. First, for men and women, we estimated an increase in YPLL of 13,349 or 8.7% between 2000 to 2006 as a result of melanoma compared with a 2.8% increase in all malignant cancers. On the other hand, there was a decrease in YPLL of 2.0% among the 4 major cancers confirming reports that melanoma mortality has increased in recent years compared with other cancer sites. 3, 38, 39 In general, the increase in melanoma mortality and YPLL is substantially higher in men than in women. However, on an individual basis and in all race/ethnicity, YPLL per melanoma death is higher among women, which implies that this cancer affects women at a younger age than men. This finding is consistent with other published studies that have reported primarily on melanoma in adolescent and young adults. 40, 41 The observed difference in premature deaths caused by melanoma in young women and men may be a result of the increased use of indoor tanning particularly by white females aged 45 and women are more likely to use indoor tanning than men. 46 Second, we estimated the annual cost associated with melanoma mortality to be $3.5 billion. Our estimates suggest that an individual who died from melanoma in 2000 through 2006 would lose an average of $413,370 in forgone lifetime earnings. On average, this estimate is 1.6 times higher than the estimates from the 4 major cancers. For all malignant cancers, the productivity loss per death was $309,879, which is 1.3 times lower than the estimate from melanoma. These findings provided consistent evidence that the economic burden of melanoma disease is substantial [9] [10] [11] and represents a serious public health concern. Further, a recent systematic review study presented a comparative melanoma disease burden between the United States and other countries. 47 The study showed that in both YPLL and productivity loss, the estimates were relatively higher in the United States compared with other industrialized countries.
Although this study demonstrates the substantial costs of melanoma to each racial/ethnic group, with non-Hispanic whites accounting for 95.1% of the estimated total melanoma costs and Hispanics accounting for 2.3%, it also highlights the potential costs that could be saved if prevention programs were designed to reduce the burden of melanoma disease among these racial/ethnic groups. In the past decade, prevention programs have been initiated to reduce the burden of melanoma. Such prevention programs have focused on reducing exposure to ultraviolet radiation by increasing knowledge and awareness through educational programs, media campaigns, and by implementing policy initiatives that encourage sun-safety practices. 48 According to the US Preventive Services Task Force, currently there is insufficient evidence to recommend for or against regular skin cancer screening including self-examination for early detection of melanoma in the adult general population. 49 However, the Task Force on Community Preventive Services found sufficient evidence to recommend intervention programs that promote and improve awareness of melanoma and other skin cancers in primary schools and recreational or tourism settings. 48 These and similar efforts from public and private health agencies and institutions may be contributing to improving the awareness of skin cancer diseases. However, these efforts may not be enough. For example, in 1935 the average lifetime risk of an American developing melanoma was 1 in 1500 and in 2009, this probability has increased to 1 in 30.
2,3
The increasing risk of melanoma underscores the importance of public and private health agencies and institutions working together to develop and implement cost-effective risk-reduction programs. Fortunately, such interventions may be currently available. For example, the US Environmental Protection Agency developed and implemented a SunWise school-based program designed to teach children how to protect themselves from overexposure to sun. 50 This program has been reported to be cost-effective with a return on investment of $2 to $4 saved in medical care costs and productivity losses for every dollar invested and could prevent more than 50 premature deaths associated with melanoma by 2015. 50 This and other prevention programs that might include changes in personal behaviors and government policies designed to reduce exposure to artificial sunlight, such as the use of indoor tanning beds, may help in reducing the mortality burden associated with melanoma.
Limitations
This study has some limitations. First, in estimating YPLL as a result of melanoma mortality, we used life table data on all race/ethnicity as a proxy for life expectancy of non-Hispanic other. This approach may have introduced some uncertainty in our estimates. Second, we used the HCA to estimate PVFLE. This approach assumes that an individual produces a stream of earnings that is valued only through employment. Therefore, it fails to recognize the costs of intangibles, which includes pain and suffering, the psychosocial consequences of cancer disease, and reductions in the quality of life. 13 Third, our analysis excludes morbidity costs associated with melanoma, which includes the productivity loss from individuals with melanoma before they die, costs of medical treatment, nonmedical costs (eg, those associated with time spent seeking cancer treatment and care), and productivity losses for caregivers. These costs represent a substantial amount of resources lost or spent because of melanoma.
CONCLUSIONS
Despite these limitations, the health burden measured by YPLL and economic cost estimates presented in this article provide evidence of significant numbers of premature deaths and substantial mortality costs associated with cutaneous melanoma during an individual's lifetime. Given the increasing incidence rate and mortality associated with melanoma in an era of declining mortality among other major cancers, it appears that current prevention efforts may not be adequate. Hence, it has been suggested that perhaps new prevention strategies that involve a multifaceted approach should be adopted. 51 This approach would include social marketing, policy change, education, and sustained intervention programs that may be required to measurably shift knowledge, attitudes, and behaviors of the population. 51 In the past, estimates of health burden and economic costs of diseases including cancer have proven useful to guide health care policy debates in the population. 21, 52 We hope that the information reported in this article would be helpful in mobilizing interests and guiding resources to enable public health decision makers to develop the right health policy and comprehensive intervention programs to decrease the burden of melanoma mortality in the United States.
Discount rate: Used to convert future dollars and future health outcomes to their present value.
APPENDIX 2: THE RELATIVE CONTRIBUTIONS OF EACH OF FOUR MAJOR CANCER SITES TO MORTALITY AND YPLL
We estimated the ratio of the relative contributions of each of the 4 major cancer sites (ie, breast, prostate, colorectal, and lung), melanoma, and all malignant cancers to years of potential life lost (YPLL) and mortality in the population. We used all malignant cancers as reference. The numerator of the ratio was the YPLL for each cancer site divided by the YPLL for all malignant cancers and expressed as a percent. The denominator was the number of deaths caused by each cancer site divided by the number of deaths caused by all malignant cancers and expressed as a percent (ie, % YPLL/% mortality). The 45-degree line (y = x) represents the line of equality, which indicates a cancer site's equal relative contribution to YPLL and mortality. A cancer site with a ratio less than 1 indicates that cancer contributes more to mortality than to the number of YPLL. On the other hand, a ratio greater than 1 indicates that cancer contributes more to YPLL than to the number of deaths.
Fig 2 shows that melanoma and breast cancer contributed more to YPLL than to mortality with ratios of 1.23 and 1.22, respectively. On the other hand, prostate cancer contributed more to mortality than to YPLL with a ratio of 0.59. 
